This is Part 7 — the final installment of the Biofilm & Kidney Stones series. Part 6 covers the vicious cycle between UTIs and kidney stones.
Throughout this series, we've built a picture that didn't exist in mainstream kidney stone advice before:
Bacteria aren't bystanders. They're building the scaffolding inside our stones. We know which bacteria are doing it. We know some foods fight biofilm while others are complicated. We know NAC shows dual-mechanism promise. And we know UTIs and stones feed each other in a cycle that biofilm connects.
The obvious next question: what's actually being done about it?
I want to be straight with you — the way I've tried to be throughout this series. The clinical pipeline is real, but it's young. Some of what I'm about to describe is in human trials right now. Some is still in animal models. None of it is available as standard care for kidney stone patients today.
But the direction is clear. And for the first time, researchers are designing treatments that target the bacterial component of kidney stones — not just the minerals.
The Most Exciting Study You Haven't Heard Of
If there's one study from the last two years that kidney stone patients should know about, it's this one.
In 2025, Massana Roquero et al. published a study in Advanced Healthcare Materials that tested something deceptively simple: what if you irrigated the surgical site with an anti-biofilm solution during kidney stone removal?
The idea came from a real clinical problem. When surgeons break apart a kidney stone — whether with laser lithotripsy or shockwave treatment — they shatter the stone's structure. Any bacteria sealed inside the stone get released into the urinary tract. This is why post-operative UTIs affect up to 30% of stone surgery patients, and why post-operative sepsis occurs in roughly 15% of cases.
The researchers tested a chitosan-based antimicrobial irrigation on fresh kidney stone fragments taken directly from patients during surgery. Chitosan is derived from chitin — the same stuff that makes up crab and shrimp shells. It has natural antimicrobial and anti-biofilm properties that have been used in wound care for years.
The results: greater than 90% reduction in bacterial burden across all stone types and bacterial strains tested. They also tested the solution on human ureteral tissue (ex vivo) and in live pig bladders — no toxic effects, no tissue damage.
This is not a clinical trial yet. Nobody has tested this protocol during actual human surgeries in a randomized trial. But the groundwork is laid. The safety data is encouraging. And the logic is compelling: if you know the stone contains bacteria, clean the site as you go.
A 2025 study showed that chitosan-based irrigation reduced bacterial burden by over 90% on kidney stone fragments — potentially preventing the post-surgical infections that restart the UTI-stone cycle. This hasn't been tested in human surgical trials yet, but the preclinical results are strong.
Bacteriophage Therapy: Viruses That Hunt Bacteria
This one sounds like science fiction, but it's real and it's further along than you might expect.
Bacteriophages — or just "phages" — are viruses that exclusively infect and kill bacteria. They're everywhere in nature. They don't infect human cells. And unlike broad-spectrum antibiotics, they can be engineered to target specific bacterial species.
Why does this matter for kidney stones? Because one of the biggest problems with the UTI-stone cycle is antibiotic resistance. Bacteria hiding inside stones develop resistance over months or years. When those bacteria are released during stone treatment, the antibiotics your doctor prescribes may not work.
Phages offer a different approach entirely. They evolve alongside bacteria. They can penetrate biofilm. And bacterial resistance to phages develops differently than resistance to antibiotics — when bacteria mutate to evade a phage, they often lose other survival advantages in the process.
The ELIMINATE Trial is the furthest along. Run by Locus Biosciences with $23.9 million in BARDA funding, it's testing LBP-EC01 — a CRISPR-enhanced phage cocktail specifically targeting E. coli in urinary tract infections. Phase 2 Part 1 results, published in The Lancet Infectious Diseases (2024), showed microbiologic cure in 14 of 16 evaluable patients. No serious adverse events. No genetic resistance detected.
Part 2 — a Phase 2/3 randomized, placebo-controlled, double-blind trial with 288 patients — began dosing in late 2024 and is currently enrolling.
This trial targets UTIs, not kidney stones directly. But E. coli is the most common bacterium found inside calcium oxalate stones. If phage therapy can clear E. coli from the urinary tract more effectively than antibiotics — including bacteria hiding in biofilm — it could break the UTI-stone cycle at its source.
Separately, researchers have developed phage cocktails specifically targeting Proteus mirabilis — the struvite stone specialist. Lab studies published in Antimicrobial Agents and Chemotherapy (2022) showed 65% biofilm mass reduction. More recent work in Scientific Reports (2025) demonstrated dual-layered pH-responsive catheter coatings that doubled the time to catheter blockage. These are preclinical — no human trials yet — but they're directly relevant to infection stone prevention.
Bacteriophages are viruses that exclusively kill bacteria — they can't infect human cells. The ELIMINATE trial is testing a CRISPR-enhanced phage cocktail for E. coli UTIs in a Phase 2/3 trial right now. If successful, it could change how we treat the bacterial infections that seed kidney stone formation.
Anti-Biofilm Stents: Devices That Fight Back
If you've had kidney stone surgery, you've probably had a ureteral stent — that plastic tube threaded between your kidney and bladder that keeps urine flowing while you heal. Stents are medically necessary. They're also miserable. And within 24 hours of insertion, bacteria start colonizing them and forming biofilm.
Stent-related biofilm is a real problem. It causes UTIs, encrustation (mineral buildup on the stent surface), and can seed new stone formation. It's one of the reasons post-surgical infections are so common.
The good news: anti-biofilm stent coatings are further along than most biofilm therapies. One is already on the market.
The Endo-Sof Radiance stent (Cook Medical) uses a covalently bonded heparin-mimetic coating that resists bacterial adhesion and mineral encrustation. Published studies by Riedl et al. (European Urology, 2002) and Cauda et al. (Journal of Endourology, 2008) showed no encrustation at 6 weeks on heparin-coated stents, compared to heavy deposits on uncoated controls. One patient had a heparin-coated stent remain clean for 10 months.
This is already FDA-cleared and commercially available. If you're facing stent placement and you're a recurrent stone former with a history of UTIs, it's worth asking your urologist about.
Beyond heparin, researchers are working on next-generation coatings:
- Zwitterionic coatings showed 96% encrustation reduction in simulated urine flow over 30 days (in vitro)
- Diamond-like carbon (DLC) coatings are commercially available and show reduced biofilm with regular replacement schedules
- Zinc oxide nanoparticle hydrogels showed over 99% antibacterial efficacy in laboratory testing
Most of these are still preclinical. But the principle is proven: coating the stent surface with materials that bacteria can't grip dramatically reduces biofilm formation. It's one of the closest-to-patient applications of anti-biofilm technology.
If you need a ureteral stent and you have a history of recurrent UTIs or stone-related infections, ask your urologist about heparin-coated stent options. They're FDA-cleared and commercially available, and published studies show significantly less bacterial colonization and encrustation compared to standard stents.
NAC: Where the Human Data Stands
We covered NAC extensively in Part 5 — its dual mechanism of biofilm disruption and crystal growth inhibition. But where does it actually stand as a clinical treatment?
Honestly? Still early.
The strongest human data comes from a small study of 17 calcium oxalate stone patients given 3 grams per day of NAC for one week. The treated group showed a 60% reduction in large urinary calcium oxalate crystals, and 3 patients passed stones spontaneously. That's intriguing — but it's 17 people for one week, with no control group. It's hypothesis-generating, not proof.
On the biofilm side, multiple in vitro studies from 2021-2025 have demonstrated NAC's ability to disrupt biofilm on urinary catheters and protect bladder epithelial cells from bacterial invasion. A 2023 study in Frontiers in Cellular and Infection Microbiology showed NAC suppressed urease activity in Proteus mirabilis — the enzyme that drives struvite stone formation. But again, these are lab studies.
The gap between "works in a petri dish" and "works in a person" is where our Canadian doctor friend in the comments rightly pushed back. Many compounds show promise in vitro and fail in vivo. NAC might be different — it has decades of safe clinical use for other conditions, and it achieves meaningful concentrations in urine after oral dosing. But "might" isn't "does."
What's needed: a properly designed randomized controlled trial of NAC in recurrent stone formers. The preclinical evidence justifies it. The safety profile supports it. The funding... well, NAC is a cheap generic supplement that can't be patented. That's great for patients if it works, and terrible for attracting the kind of pharmaceutical investment that drives large clinical trials.
What's Not Coming (Yet)
Let me be honest about what doesn't exist yet, because I think knowing the gaps is as important as knowing the progress.
There is no anti-biofilm drug approved for kidney stone prevention. Nothing you can take as a pill that targets biofilm in the kidneys specifically. NAC, garlic, and the other approaches we discussed in this series are supplements and foods with anti-biofilm properties — not targeted therapies.
There is no clinical protocol that combines stone removal with biofilm eradication. The chitosan irrigation study is promising but hasn't been tested in a surgical trial. No urologist today has a standardized protocol for addressing bacteria released during stone procedures.
Nobody has replicated the UCLA finding in a large clinical cohort. The Scotland/Wong PNAS study is strong science — published in one of the world's top journals, with compelling mechanistic data. But it hasn't yet been independently replicated by other groups, and the UCLA team hasn't published follow-up work (as of this writing). This doesn't mean it's wrong. It means the field is young.
There are no phage therapy products approved for UTIs in the US or EU. The ELIMINATE trial is promising and well-funded, but Phase 2/3 trials take years to complete, and approval after a successful trial takes more years. Optimistically, if everything goes perfectly, we might see a phage therapy for UTIs in 3-5 years. For kidney stone biofilm specifically, add more time.
No anti-biofilm therapy is currently approved for kidney stone treatment or prevention. The treatments described in this article range from commercially available (heparin-coated stents) to early clinical trials (phage therapy) to preclinical research (chitosan irrigation). Don't stop proven strategies — hydration, dietary management, prescribed medications — while waiting for emerging therapies.
So What Do You Do Right Now?
This is the question that matters. You can't prescribe yourself phage therapy. You can't ask your surgeon to irrigate with chitosan (yet). The clinical pipeline is promising but it's not at your doorstep.
Here's what you can do today, informed by what we've learned in this series:
1. Keep tracking your oxalate. The biofilm discovery doesn't change this. Oxalate is still the building material. Reducing it is still the single most actionable thing you control. Start here if you haven't.
2. Stay hydrated. Dilute urine fights both sides — reduces mineral supersaturation and creates a less hospitable environment for bacterial colonization.
3. Eat anti-biofilm foods. Garlic, lemon water, kefir, ginger — these are low-risk additions to a kidney stone prevention diet that may help create conditions where biofilm is harder to establish.
4. Discuss NAC with your doctor. Not as a proven treatment, but as a supplement with a plausible dual mechanism and a solid safety record. Know the caveats.
5. If you get recurrent UTIs, connect the dots. Tell your urologist about your UTI history. Ask for stone cultures, not just urine cultures. Push for your doctors to communicate with each other if you're seeing separate specialists.
6. Ask about coated stents. If you need stent placement, ask your urologist about heparin-coated options. This is the one anti-biofilm technology that's already available and FDA-cleared.
7. Watch this space. The biofilm-kidney stone field is moving fast. The UCLA discovery was published in January 2026. Chitosan irrigation, phage therapy, next-generation stent coatings — these are active research areas with real funding and real publications. What's preclinical today could be in trials in a few years.
Closing the Series
When I started writing this series, I thought I was going to explain one study. The UCLA paper was compelling, and I wanted to make sense of it for people like me — stone formers who feel like they're doing everything right and still getting blindsided.
Seven articles later, I've realized it's bigger than one study. It's a shift in how we understand kidney stones. Not just as a chemistry problem — too much oxalate meets too much calcium — but as a biology problem where living organisms are actively constructing the conditions for stones to form.
That doesn't make the chemistry less important. You still need to track your oxalate. You still need to drink water. You still need to follow your urologist's advice. Those are the tools we have right now, and they work.
But understanding the bacterial component gives context to questions that have haunted stone formers for years: Why did I get another stone when I was doing everything right? Why do my UTIs keep coming back? Why didn't the antibiotics work?
Those questions have better answers now. And as the clinical pipeline matures — as chitosan irrigation gets tested in surgery, as phage therapy trials complete, as anti-biofilm stent technology advances — those answers will eventually lead to treatments.
We're not there yet. But we know where we're going. And in the meantime, every low-oxalate meal, every glass of water, every clove of garlic is one less brick handed to the bacteria building your stones.
Keep tracking. It matters more than ever.
This is the final article in the Biofilm & Kidney Stones series. Start from Part 1 to read the complete series, or jump to any part: Part 2: Which Bacteria | Part 3: The Cranberry Paradox | Part 4: Anti-Biofilm Foods | Part 5: NAC | Part 6: The UTI-Stone Cycle